罗沙司他治疗维持性血液透析患者难治性肾性贫血的效果分析

Effect Analysis of Roxadustat in Treatment of Refractory Renal Anemia in Maintenance Hemodialysis Patients

目的:探究对维持性血液透析(MHD)患者难治性肾性贫血给予罗沙司他治疗的效果及安全性。方法:选取2021年2月-2022年2月龙川县人民医院收治的MHD合并难治性肾性贫血患者76例为观察对象,根据随机数字表法分为对照组与观察组,各38例。对照组行重组人促红细胞生成素治疗,观察组行罗沙司他治疗,比较两组患者贫血指标、铁代谢指标、炎性因子水平及不良反应发生率。结果:治疗后,两组患者血细胞比容、血红蛋白、红细胞计数水平均提高,观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者血清铁(SI)、血清铁饱和度(ISAT)、总铁结合力(TIBC)水平均提高,不饱和铁结合力(UIBC)水平下降,观察组SI、ISAT与TIBC水平高于对照组,UIBC水平低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者白细胞介素-6、C反应蛋白与肿瘤坏死因子α水平均降低,观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:罗沙司他治疗MHD合并难治性肾性贫血患者疗效确切,可促进患者贫血指标、铁代谢指标改善,减轻患者炎性反应,降低不良反应发生率,安全性较高。

Objective:To explore the efficacy and safety of roxadustat in the treatment of refractory renal anemia in maintenance hemodialysis(MHD)patients.Methods:A total of 76 patients with MHD complicated with refractory renal anemia who were admitted to Longchuan County People's Hospital from February 2021 to February 2022 were selected as the observation objects.They were divided into control group and observation group according to random number table method,with 38 cases in each group.The control group was treated with recombinant human erythropoietin,and the observation group was treated with roxadustat.The anemia index,iron metabolism index,inflammatory factor level and adverse reaction rate of the two groups were compared.Results:After treatment,the hematocrit,hemoglobin and red blood cell count levels in the two groups increased,and the levels in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).After treatment,the serum iron(SI),serum iron saturation(ISAT)and total iron-binding capacity(TIBC)levels in the two groups increased,and the unsaturated iron-binding capacity(UIBC)levels decreased,and the levels of SI,ISAT and TIBC in the observation group were higher than those in the control group,and the UIBC levels were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the levels of interleukin-6,C-reactive protein and tumor necrosis factorαin two groups decreased,and the levels in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:In the treatment of patients with MHD complicated with refractory renal anemia,roxadustat has a definite curative effect,it can promote the improvement of anemia indicators and iron metabolism indicators,alleviate the inflammatory reaction of patients,reduce the incidence of adverse reaction and have high safety.